M&A Deal Summary |
|
---|---|
Date | 2010-06-09 |
Target | OSI Pharmaceuticals |
Sector | Life Science |
Buyer(s) | Astellas Pharma |
Deal Type | Add-on Acquisition |
Deal Value | 4.0B USD |
Advisor(s) | Centerview Partners Solomon Partners (Financial) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1923 |
Sector | Life Science |
Employees | 14,754 |
Revenue | 1.60T JPY (2024) |
Astellas Pharma is a pharmaceutical company committed to the therapeutic fields of urology, immunology, oncology, neuroscience and DM complications and metabolic diseases. Astellas Pharma was incorporated in 1923 and is based in Tokyo, Japan.
DEAL STATS | # |
---|---|
Overall | 2 of 14 |
Sector (Life Science) | 2 of 13 |
Type (Add-on Acquisition) | 2 of 14 |
State (New York) | 1 of 1 |
Country (United States) | 2 of 11 |
Year (2010) | 1 of 1 |
Size (of disclosed) | 2 of 10 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2007-11-27 |
Agensys
Santa Monica, California, United States Astellas Pharma US, Inc., is the U.S. affiliate of Astellas Pharma Inc., Japan’s second largest pharmaceutical company and ranked within the top 20 in the global market. Astellas Pharma US is located in Deerfield, Illinois, and is the company'sheadquarters for the Americas. |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2011-05-16 |
Perseid Therapeutics
Redwood City, California, United States Perseid Therapeutics LLC engages in the discovery, and research and development. |
Buy | - |